Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women

NCT03951402 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Prolonged QTc Interval
Pharmacokinetic

Interventions

DRUG: 100 mg CG5503 (tapentadol hydrochloride) PR tablet
DRUG: Placebo matching CG5503 PR tablet
DRUG: Placebo matching moxifloxacin capsule
DRUG: 400 mg Moxifloxacin tablet (overencapsulated)

Sponsor

Grünenthal GmbH